These studies utilize various EV types, including T-cell-derived vesicles, bacterial outer membrane vesicles (OMVs), and TEX, to improve tumor targeting, modulate immune responses, and block checkpoint pathways. This evidence concerns the gene TEX46 and neoplasm.